Next Article in Journal
Correction: Masi et al. Araufuranone: A New Phytotoxic Tetrasubstituted Dihydrofuro[3,2-b]furan-2(5H)-One Isolated from Ascochyta araujiae. Biomolecules 2022, 12, 1274
Next Article in Special Issue
Peering into the Brain’s Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders
Previous Article in Journal
Cellular Response to Bone Morphogenetic Proteins-2 and -7 Covalently Bound to Photocrosslinked Heparin–Diazoresin Multilayer
Previous Article in Special Issue
[18F]GE-180-PET and Post Mortem Marker Characteristics of Long-Term High-Fat-Diet-Induced Chronic Neuroinflammation in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 5
10.3390/biom13050843
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET

by
Chloé Laurencin
1,2,3,4,5,
Sophie Lancelot
1,2,3,4,6,7,
Inès Merida
6,
Nicolas Costes
6,
Jérôme Redouté
6,
Didier Le Bars
6,7,
Philippe Boulinguez
1,2,3,4 and
Bénédicte Ballanger
1,2,3,4,*
1
Université de Lyon, 69622 Lyon, France
2
Université Claude Bernard Lyon 1, 69100 Villeurbanne, France
3
INSERM U1028, Lyon Neuroscience Research Center (CRNL), 69000 Lyon, France
4
CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), 69000 Lyon, France
5
Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, Hospices Civils de Lyon, 69677 Bron, France
6
CERMEP-Imagerie du Vivant, 69500 Bron, France
7
Hospices Civils de Lyon, 69677 Bron, France
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(5), 843; https://doi.org/10.3390/biom13050843
Submission received: 27 April 2023 / Revised: 12 May 2023 / Accepted: 12 May 2023 / Published: 15 May 2023
(This article belongs to the Special Issue Novel Imaging Biomarkers for Brain PET Imaging)
Browse Figures
Versions Notes

Abstract

:
The neurofunctional basis of the noradrenergic (NA) system and its associated disorders is still very incomplete because in vivo imaging tools in humans have been missing up to now. Here, for the first time, we use [11C]yohimbine in a large sample of subjects (46 healthy volunteers, 23 females, 23 males; aged 20–50) to perform direct quantification of regional alpha 2 adrenergic receptors’ (α2-ARs) availability in the living human brain. The global map shows the highest [11C]yohimbine binding in the hippocampus, the occipital lobe, the cingulate gyrus, and the frontal lobe. Moderate binding was found in the parietal lobe, thalamus, parahippocampus, insula, and temporal lobe. Low levels of binding were found in the basal ganglia, the amygdala, the cerebellum, and the raphe nucleus. Parcellation of the brain into anatomical subregions revealed important variations in [11C]yohimbine binding within most structures. Strong heterogeneity was found in the occipital lobe, the frontal lobe, and the basal ganglia, with substantial gender effects. Mapping the distribution of α2-ARs in the living human brain may prove useful not only for understanding the role of the NA system in many brain functions, but also for understanding neurodegenerative diseases in which altered NA transmission with specific loss of α2-ARs is suspected.

1. Introduction

The noradrenergic (NA) system has been implicated in the regulation of brain regions involved in numerous motor and non-motor functions, in particular arousal, sensory processing, attention, working memory, cognitive control, reward, mood, and emotion [1,2,3,4]. Accordingly, disruptions of NA functions have been associated with several disorders, with a potentially important role in neurodegenerative diseases [5,6,7,8,9,10]. This makes the NA system an important molecular target for drug development [11,12,13,14,15]. However, knowledge of the neurofunctional basis of the NA system on which such an endeavor is based is still incomplete and highly controversial. A major reason for the lack of knowledge is the lack of specific in vivo imaging tools in humans.
Detailed mapping of anatomical distribution of α2-adrenergic receptors (ARs) in the human brain is essential for understanding the neurochemistry of neurodegenerative and neuropsychiatric disorders. Until now, it has only been studied ex vivo using quantitative autoradiography [16,17,18,19,20,21,22,23,24]. Although these studies have provided important insights, they have substantial limitations inherent to the technique. Findings obtained with autoradiography have highlighted dramatic species differences in the levels of α2-ARs [18] in several brain areas, making it difficult to extrapolate findings from animals to humans and complicating the interpretation of behavioral studies in rodents. The results obtained with autoradiography in humans are based on fragmentary analyses, and caveats are found in the restrictions of the tissue samples analyzed, such as samples of the human frontal cortex only related to Brodmann’s area 10 [22] or Brodmann’s area 9 [17,25]. Finally, autoradiography findings are limited by the sample size that can be used (ranging from 2 [26] to 22 [21] subjects).
In vivo imaging of the NA system has recently become feasible in humans with the development of a novel PET radiotracer: the [11C]yohimbine [27,28]. [11C]yohimbine binds with high selectivity to all α2-ARs subtypes [29]. This represents a great opportunity to fill in missing data in the living human brain by directly quantifying regional α2-AR availability. Here, for the first time, we use [11C]yohimbine in a large sample of subjects to map the distribution of α2-ARs in the living human brain.

2. Materials and Methods

2.1. Participants

Forty-six healthy subjects (23 males (mean age ± SD, 35.1 ± 9.4; range 20–50 y) and 23 females (mean age ± SD, 35.5 ± 9; range 20–50 y)) were selected to participate in the study. Male and female subjects were recruited to achieve a homogeneous age distribution between 20 and 50 years old. Exclusion criteria were as follows: ferromagnetic implanted materials, claustrophobia, pregnancy, history of noradrenergic medications, history of dependence on alcohol or other drugs of abuse, diagnosis of other neurological or psychiatric disorders, and history of head trauma. None of the participants were smokers.

2.2. PET Procedures

[11C]yohimbine was synthesized as previously described [29]. The radiochemical purities of syntheses used for the study were greater than 95%, with corresponding molar activities of 70 ± 29 GBq/μmol at the end of synthesis. All subjects received an intravenous bolus injection of 370 MBq ± 10% of [11C]yohimbine. List-mode PET data were acquired, during the 90 min from the injection of the tracer, simultaneously with 3T MRI data (Dixon T1, anatomic MPRAGE T1) on a Siemens mMR Biograph system.

2.3. Image Processing

Raw PET data were motion corrected [30], and then rebinned into 24 time frame (variable length frames, 8 × 15 s, 3 × 60 s, 5 × 120 s, 1 × 300 s, 7 × 600 s) sinograms for dynamic reconstruction. Images were reconstructed using 3D ordinary Poisson-ordered subset expectation maximization (OP-OSEM 3D), incorporating the system point spread function using 3 iterations of 21 subsets. Sinograms were corrected for scatter, randoms, normalization, and attenuation [31]. Reconstructions were performed with a zoom of 2 in a matrix of 172 × 172 voxels, yielding a voxel size of 2.03 × 2.03 × 2.08 mm3, with a 4 mm 3D post-reconstruction Gaussian filtering. Individual MRI T1 was normalized to the MNI space (Montreal Neurological Institute template of the International Consortium for Brain Mapping Project) using the Segment function of SPM 12 [32]. Labeling of the structural brain regions was performed using the multi-atlas propagation with enhanced registration (MAPER) methodology [33], and the 83-region Hammers atlas [34]. After segmentation, regional time–activity curves (TAC) were extracted, and the non-displaceable binding potential (BPND) obtained with the Simplified Reference Tissue Model (SRTM) was calculated in the different ROIs with the corpus callosum taken as the reference region [28].

2.4. Statistical Analysis

Statistical analysis was performed using Rstudio (https://github.com/rstudio/rstudio, accessed on 1 September 2022). Results with p < 0.05 were considered statistically significant. First, we conducted a coarse-grained analysis by applying a 13 ROI (Hippocampus, Occipital Lobe, Cingulate Gyrus, Frontal Lobe, Parietal Lobe, Thalamus, Parahippocampus, Insula, Temporal Lobe, Basal Ganglia, Amygdala, Cerebellum, Raphe nucleus) × 2 side (left, right) × 2 sex (male, female) ANOVA. Then, we performed fine-grained analyses by fractionating the 6 main ROIs according to the Hammers atlas [34]. For each one of these main ROIs (Occipital lobe, Cingulate gyrus, Frontal Lobe, Parietal Lobe, Temporal Lobe, Basal Ganglia), a n Subregion (varying from 2 to 9 according to the ROI) × 2 side (left, right) × 2 gender (male, female) ANOVA was performed.
For illustrative purposes only, SPM12 was used for whole brain voxel-based analysis on the spatially normalized and smoothed parametric BP images of the 46 control subjects. To assess sex-related variability, we applied a two-sample t test between males and females, with individual BP values taken as covariates for interindividual adjustment. Statistical parametric maps of the t statistic were computed with a threshold of p = 0.005 uncorrected at the voxel level.

3. Results

3.1. Regional ROI Analysis

Table 1 shows BPND values for the 13 anatomical regions. The results show a main effect of region (F(11, 4090) = 118.53, p < 0.001) (Table 2) as well as a main effect of sex (F(1, 4090) = 29.11, p < 0.001) without significant difference between sides (p = 0.1). An interaction between sex and region (F(11, 4090) = 2.63, p < 0.005) indicates that significant differences between females and males are observed in the cerebellum (p = 0.01), the frontal and parietal lobes (p < 0.001), and the hippocampus (p < 0.001). As there was no significant difference between left and right BPND, values were pooled to determine the mean BPND and the standard deviation (SD) within each ROI (Table 1).

3.2. Subregional ROI Analyses

Within the occipital lobe, a significant main effect of region is observed (F(2, 264) = 87.5; p < 0.001) showing that [11C]yohimbine BPND is not different between the cuneus (0.69 ± 0.17) and the lingual gyrus (0.66 ± 0.17), two regions characterized by a stronger BP than the lateral parts of the occipital lobe (0.40 ± 0.14, ps < 0.001).
Within the cingulate gyrus, a significant main effect of region is reported (F(1, 176) = 24.6; p < 0.001), showing that [11C]yohimbine BPND is higher in its posterior part (PCC, 0.61 ± 0.14) than in its anterior part (ACC, 0.51 ± 0.13).
Within the frontal lobe, significant main effects of sex and regions are observed, without interaction. Males have overall higher [11C]yohimbine BPND than females (F(1, 1068) = 16.7 p < 0.001). Among the frontal subregions, the highest [11C]yohimbine BPND is found within the straight gyrus (0.65 ± 0.15), followed by the orbital gyrus (0.58 ± 0.16), the presubgenual ACC (0.57 ± 0.16), and the middle frontal gyrus (0.54 ± 0.15). Intermediate [11C]yohimbine BPND is observed in the superior frontal gyrus (0.51 ± 0.15), the inferior frontal gyrus (0.49 ± 0.13), the precentral gyrus (0.43 ± 0.14), and the subgenual ACC (0.42 ± 0.13), while the lowest [11C]yohimbine BPND is observed in the subcallosal area (0.36 ± 0.13). p-value thresholds are shown in Table 3.
Within the parietal lobe, only a significant effect of sex is observed (F(1, 352) = 14.16; p < 0.001), with males (0.51 ± 0.14) having overall higher [11C]yohimbine BPND than females (0.45 ± 0.13).
Within the temporal lobe, significant main effects of sex (F(1, 624) = 4.2; p = 0.04), side (F(1, 624) = 15.03; p < 0.001), and region (F(4, 624) = 22.2; p < 0.001) are observed with no significant interaction between the three independent variables. Males (0.39 ± 0.15) have overall higher [11C]yohimbine BPND than females (0.36 ± 0.14). BPND is higher on the right side (0.40 ± 0.14) than on the left side (0.36 ± 0.14). Finally, [11C]yohimbine BPND is higher in the posterior temporal lobe (0.47 ± 0.13) than in a group of subregions composed of the fusiform gyrus (0.41 ± 0.13), the superior temporal gyrus (0.38 ± 0.15), and in the middle and inferior temporal gyrus (0.37 ± 0.12) which show intermediate binding levels. A lower [11C]yohimbine BPND was reported in the anterior temporal lobe (0.32 ± 0.13).
Within the basal ganglia, a significant main effect of region is reported (F(4, 440) = 60.54; p < 0.001) showing that [11C]yohimbine BPND is higher in the nucleus accumbens (0.41 ± 0.14), the putamen (0.40 ± 0.17), and the pallidum (0.39 ± 0.15) than in the substantia nigra (0.19 ± 0.14) and the caudate (0.17 ± 0.12).
We summarized all the BPND values in Table 4.

3.3. Whole Brain Illustrations

The distribution of α2-ARs in the living human brain can be illustrated using the average parametric images of [11C]yohimbine BPND values overlaid on an average T1-weighted image of the 46 subjects (Figure 1).
The gender effect found in the main coarse-grained and fine-grained statistical analyses can be illustrated using the statistical parametric maps comparing females to males (Figure 2).

4. Discussion

In this paper, we present for the first time a complete human brain mapping of the α2-ARs in vivo. Our data confirm the widespread distribution of these receptors throughout the human brain. The regional distribution of [11C]yohimbine binding is broadly consistent with the major findings of post-mortem human brain studies [17,19,20,21,22], further validating the use of the radiotracer. More specifically, the present dataset provides a complete and refined picture of subregional variations in α2-ARs based on 35 anatomical subdivisions of the Hammers’ probabilistic atlas [34,35]. This statistical mapping is intended to provide a tool for interpreting current issues on the physiological bases of NA functions in the human brain and for conducting future investigations of the role of α2-ARs in regulating NA neurotransmission in healthy and clinical conditions. Furthermore, this statistical mapping also raises new issues such as gender effects.

4.1. Regional Distribution of [11C]yohimbine

Important regional variations of α2-ARs availability are observed. The highest [11C]yohimbine binding was seen in the hippocampus followed by the occipital lobe, the cingulate gyrus, and the frontal lobe. Regions with moderate levels of specific binding included the parietal lobe, the thalamus, the parahippocampus, the insula, and the temporal lobe. Low [11C]yohimbine binding was found in the basal ganglia, amygdala, cerebellum, and raphe nucleus. This broad overview does not contradict quantitative autoradiographic studies [16,18,20,21,24].

4.2. Subregional Variations in α2-ARs Availability

With the exception of the parietal lobe showing remarkable homogeneity (with intermediate to high levels of binding), parcellating the brain into anatomical subregions pinpoints important variations of [11C]yohimbine binding within each structure.
The occipital lobe presents a substantial variation of specific binding ranging from very high to intermediate/low, with the medial structures of the visual cortex (cuneus and lingual gyrus) showing the highest binding of all ROIs, whereas the lateral parts of the occipital lobe are characterized by a binding level comparable to structures of the basal ganglia. This strong heterogeneity has been ignored in previous studies, either because only medial regions were examined (e.g., primary visual cortex) [20,21,23] or because global indexes of occipital binding were calculated [24].
The frontal lobe is also characterized by high heterogeneity (Table 3 and Figure 2). A high level of binding was found in the presubgenual ACC and in the straight, orbital, and middle frontal gyri. A medium level of binding was found in the subgenual ACC and in the inferior, superior, and prefrontal gyri. A low level of binding was found in the subcallosal area. These variations were not detected, or even taken in account, in previous autoradiographic studies of the frontal cortex with only a few numbers of subregions of interest (e.g., BA 9 in [17,36,37]; BA 8–9 in [38]; BA 10 in [22]). This observation may prove crucial for understanding the complex and controversial roles of the NA system in the many functions supported by the frontal lobe [39,40,41,42,43].
Interestingly, while the basal ganglia as a whole shows [11C]yohimbine binding lying in the low range (Table 1), it is worth mentioning that there are important regional variations between the different nuclei. While the nucleus accumbens, the putamen and pallidum show intermediate binding, and the caudate and the substantia nigra exhibit almost negligible binding (Table 4). This complements the former observation obtained with experimental animal studies, which revealed higher levels of the α2A-ARs in the nucleus accumbens than in the caudate [44].
Finally, subregions of the thalamus could not be assessed with the Hammers atlas. However, in contrast to the above data, heterogeneous distribution of α2-ARs is expected from human [21] and animal literature [45,46], with concentrations in the midline, pulvinar, and posterior (intralaminar) nuclei as well as in visual and auditory relay nuclei (geniculate nuclei).

4.3. New Issues

Our consistent sample of subjects allowed for statistical comparisons between women and men. For the first, differences were found in the hippocampus, cerebellum, and frontal and parietal lobes. Interestingly, while the [11C]yohimbine binding in the hippocampus was higher for females than males, the opposite pattern was observed in the other regions.
The higher BPND could reflect changes in both pre- and postsynaptic receptors. On the one hand, it can be interpreted as reflecting a higher density of α2-ARs, but on the other hand, higher BPND values can also be interpreted as reflecting a higher availability of α2-ARs sites due to a lower concentration of NA (given that [11C]yohimbine is sensitive to endogenous variations of NA concentration [47]). This effect could be explained by the fact that central α2-ARs function would be attenuated by estrogen concentration and, as a consequence, would be relatively “blunted” in females. Some arguments come from animal studies showing that hypothalamic α2-ARs decrease following estrogen treatment in ovariectomized rats [48,49], leading α2-AR-mediated inhibition of NA release [50,51]. Further arguments come from clinical studies showing a gender effect in the prevalence of α2-AR-related disorders, such as mood and anxiety [52], which are almost twice as high in females than in males [53]. Our results highlight the need to consider this gender effect in all types of studies of the NA system.

4.4. Limitations

The main limitation of the present study, and by extension of the use of [11C]yohimbine PET, is the fact that it does not differentiate between the different subtypes of α2-ARs that have been characterized pharmacologically (α2A, α2B, α2C) [54]. The physiological relevance of these subtypes cannot be fully elucidated without specific radioligands, but the differences that have already been identified between the different α2 receptor subtypes must be acknowledged for interpreting [11C]yohimbine PET data. In particular, the α2A-subytpe is known to be the main inhibitory presynaptic feedback receptor [55,56,57] with α2C to a less extent. These two subtypes are also known as heteroceptors that inhibit the release of dopamine and serotonin [58,59] making the problem even more complex. In addition, there are α2-ARs both at the pre- and postsynaptic sites, which always makes interpretation of the results difficult. Nevertheless, it is broadly considered that the presynaptic inhibitory autoreceptors located on noradrenergic neurons in the locus coeruleus play a crucial role in the regulation of the release and synthesis of noradrenaline, while the postsynaptic α2-ARs located in the widely distributed projection areas of the neurons throughout the cortex modulate the signaling pathways [60,61]. Finally, it must be acknowledged that we did not apply partial volume correction, meaning that these data must be interpreted with caution, in particular with regard to the relative low binding in small structures or to the absence of differences between nearby regions due to the spillover effect.

5. Conclusions

The α2-ARs play a key role in regulating NA neurotransmission [62,63], but their in vivo imaging in humans was not possible until now. Providing a technical solution, [11C]yohimbine PET allowed for the mapping of their distribution in the living human brain, which will help interpreting past and future investigations on the role of the NA system in numerous brain functions in healthy as well as in various clinical conditions. This is all the more important as altered NA transmission with specific loss of α2-ARs is currently suspected to play a critical role in both the symptoms and progression of some neurodegenerative and mood disorders [9,22].

Author Contributions

Conceptualization, C.L., S.L., P.B. and B.B.; methodology, S.L., N.C. and B.B.; software, I.M., J.R. and N.C.; validation, S.L. and D.L.B.; formal analysis, C.L., I.M., N.C. and B.B.; investigation, C.L., S.L., I.M., N.C., D.L.B. and B.B.; resources, P.B. and B.B.; data curation, B.B.; writing—original draft preparation, P.B. and B.B.; writing—review and editing, C.L., S.L., I.M., N.C., J.R., P.B. and B.B.; visualization, C.L., P.B. and B.B.; supervision, B.B.; project administration, B.B.; funding acquisition, B.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the French National Agency of Research (grant number ANR-16-CE37-0014 to B.B).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethical Committee in Biomedical Research (N° CPP 19_01_02/N°EudraCT 2018-003999-13).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The authors will be happy to support request for a formal data sharing agreement.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Holland, N.; Robbins, T.W.; Rowe, J.B. The Role of Noradrenaline in Cognition and Cognitive Disorders. Brain 2021, 144, 2243–2256. [Google Scholar] [CrossRef] [PubMed]
  2. Sara, S.J.; Bouret, S. Orienting and Reorienting: The Locus Coeruleus Mediates Cognition through Arousal. Neuron 2012, 76, 130–141. [Google Scholar] [CrossRef] [PubMed]
  3. Berridge, C.W.; Waterhouse, B.D. The Locus Coeruleus–Noradrenergic System: Modulation of Behavioral State and State-Dependent Cognitive Processes. Brain Res. Rev. 2003, 42, 33–84. [Google Scholar] [CrossRef] [PubMed]
  4. Aston-Jones, G.; Cohen, J.D. Adaptive Gain and the Role of the Locus Coeruleus-Norepinephrine System in Optimal Performance. J. Comp. Neurol. 2005, 493, 99–110. [Google Scholar] [CrossRef] [PubMed]
  5. Singh, S. Noradrenergic Pathways of Locus Coeruleus in Parkinson’s and Alzheimer’s Pathology. Int. J. Neurosci. 2020, 130, 251–261. [Google Scholar] [CrossRef]
  6. Weinshenker, D. Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. Trends Neurosci. 2018, 41, 211–223. [Google Scholar] [CrossRef]
  7. Shin, E.; Rogers, J.T.; Devoto, P.; Björklund, A.; Carta, M. Noradrenaline Neuron Degeneration Contributes to Motor Impairments and Development of L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson’s Disease. Exp. Neurol. 2014, 257, 25–38. [Google Scholar] [CrossRef]
  8. Delaville, C.; Deurwaerdère, P.D.; Benazzouz, A. Noradrenaline and Parkinson’s Disease. Front. Syst. Neurosci. 2011, 5, 31. [Google Scholar] [CrossRef]
  9. Marien, M.R.; Colpaert, F.C.; Rosenquist, A.C. Noradrenergic Mechanisms in Neurodegenerative Diseases: A Theory. Brain Res. Rev. 2004, 45, 38–78. [Google Scholar] [CrossRef]
  10. Braak, H.; Tredici, K.D.; Rüb, U.; de Vos, R.A.I.; Jansen Steur, E.N.H.; Braak, E. Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef]
  11. Cui, K.; Yang, F.; Tufan, T.; Raza, M.U.; Zhan, Y.; Fan, Y.; Zeng, F.; Brown, R.W.; Price, J.B.; Jones, T.C.; et al. Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice. ASN Neuro 2021, 13, 175909142110097. [Google Scholar] [CrossRef] [PubMed]
  12. Caraci, F.; Merlo, S.; Drago, F.; Caruso, G.; Parenti, C.; Sortino, M.A. Rescue of Noradrenergic System as a Novel Pharmacological Strategy in the Treatment of Chronic Pain: Focus on Microglia Activation. Front. Pharmacol. 2019, 10, 1024. [Google Scholar] [CrossRef] [PubMed]
  13. O’Neill, E.; Harkin, A. Targeting the Noradrenergic System for Anti-Inflammatory and Neuroprotective Effects: Implications for Parkinson’s Disease. Neural Regen. Res. 2018, 13, 1332. [Google Scholar] [CrossRef] [PubMed]
  14. Nutt, D.J.; McAllister–Williams, R.H. Noradrenaline—The Forgotten Amine? J. Psychopharmacol. 2013, 27, 657–658. [Google Scholar] [CrossRef]
  15. Fornai, F.; di Poggio, A.; Pellegrini, A.; Ruggieri, S.; Paparelli, A. Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics. Curr. Med. Chem. 2007, 14, 2330–2334. [Google Scholar] [CrossRef]
  16. Probst, A.; Cortés, R.; Palacios, J.M. Distribution of A2-Adrenergic Receptors in the Human Brainstem: An Autoradiographic Study Using [3H]p-Aminoclonidine. Eur. J. Pharmacol. 1984, 106, 477–488. [Google Scholar] [CrossRef]
  17. Pazos, A. Aa-Adrenoceptors in Human Forebrain: Autoradiographic Visualization and Biochemical Parameters Using the Agonist [AH]UK-14304. Brain Res. 1988, 475, 361–365. [Google Scholar] [CrossRef]
  18. Jones, C.R.; Palacios, J.M. Autoradiography of Adrenoceptors in Rat and Human Brain: α-Adrenoceptor and Idazoxan Binding Sites. In Progress in Brain Research; Elsevier: Amsterdam, The Netherlands, 1991; Volume 88, pp. 271–291. ISBN 978-0-444-81394-7. [Google Scholar]
  19. Vos, H.; Vauquelin, G.; Keyser, J.; Backer, J.-P.; Liefde, I. Regional Distribution of α2A- and α2B-Adrenoceptor Subtypes in Postmortem Human Brain. J. Neurochem. 1992, 58, 1555–1560. [Google Scholar] [CrossRef]
  20. Pascual, J.; Del Arco, C.; Gonzalez, A.; Diaz, A.; del Olmo, E.; Pazos, A. Regionally Specific Age-Dependent Decline in α2-Adrenoceptors: An Autoradiograpic Study in Human Brain. Neurosci. Lett. 1991, 133, 279–283. [Google Scholar] [CrossRef]
  21. Pascual, J.; del Arco, C.; Gonzalez, A.; Pazos, A. Quantitative Light Microscopic Autoradiographic Localization of A2-Adrenoceptors in the Human Brain. Brain Res. 1992, 582, 116–127. [Google Scholar] [CrossRef]
  22. Ordway, G.A.; Jaconetta, S.M.; Halaris, A.E. Characterization of Subtypes of Alpha-2 Adrenoceptors in the Human Brain. J. Pharmacol. Exp. Ther. 1993, 264, 967–976. [Google Scholar] [PubMed]
  23. Fagerholm, V.; Rokka, J.; Nyman, L.; Sallinen, J.; Tiihonen, J.; Tupala, E.; Haaparanta, M.; Hietala, J. Autoradiographic Characterization of A2C-Adrenoceptors in the Human Striatum. Synapse 2008, 62, 508–515. [Google Scholar] [CrossRef] [PubMed]
  24. Vos, H.D.; Convents, A.; Keyser, J.D.; Backer, J.-P.D.; Megena, V.; Ebinger, G.; Vauquelin, G. Autoradiographic Distribution of A2 Adrenoceptors, NAIBS, and 5-I-IT1A Receptors in Human Brain Using [3H]Idazoxan and [3H]Rauwolscine. Brain Res. 1991, 566, 13–20. [Google Scholar] [CrossRef] [PubMed]
  25. Sastre, M.; Garcia-Sevilla, J.A. Opposite Age-Dependent Changes of A2A-Adrenoceptors and Nonadrenoceptor [3H]Idazoxan Binding Sites (I2-Imidazoline Sites) in the Human Brain: Strong Correlation of I2 with Monoamine Oxidase-B Sites. J. Neurochem. 1993, 61, 881–889. [Google Scholar] [CrossRef] [PubMed]
  26. Biegon, A.; Mathis, C.A.; Budinger, T.F. Quantitative in Vitro and Ex Vivo Autoradiography of the A2-Adrenoceptor Antagonist [3H]Atopamezole. Eur. J. Pharmacol. 1992, 224, 27–38. [Google Scholar] [CrossRef]
  27. Nahimi, A.; Jakobsen, S.; Munk, O.L.; Vang, K.; Phan, J.A.; Rodell, A.; Gjedde, A. Mapping 2 Adrenoceptors of the Human Brain with 11C-Yohimbine. J. Nucl. Med. 2015, 56, 392–398. [Google Scholar] [CrossRef]
  28. Laurencin, C.; Lancelot, S.; Gobert, F.; Redouté, J.; Mérida, I.; Iecker, T.; Liger, F.; Irace, Z.; Greusard, E.; Lamberet, L.; et al. Modeling [11C]Yohimbine PET Human Brain Kinetics with Test-Retest Reliability, Competition Sensitivity Studies and Search for a Suitable Reference Region. NeuroImage 2021, 140, 118328. [Google Scholar] [CrossRef]
  29. Jakobsen, S.; Pedersen, K.; Smith, D.F.; Jensen, S.B.; Munk, O.L.; Cumming, P. Detection of A2-Adrenergic Receptors in Brain of Living Pig with 11C-Yohimbine. J. Nucl. Med. 2006, 47, 2008–2015. [Google Scholar]
  30. Reilhac, A.; Merida, I.; Irace, Z.; Stephenson, M.C.; Weekes, A.A.; Chen, C.; Totman, J.J.; Townsend, D.W.; Fayad, H.; Costes, N. Development of a Dedicated Rebinner with Rigid Motion Correction for the MMR PET/MR Scanner, and Validation in a Large Cohort of 11C-PIB Scans. J. Nucl. Med. 2018, 59, 1761–1767. [Google Scholar] [CrossRef]
  31. Mérida, I.; Reilhac, A.; Redouté, J.; Heckemann, R.A.; Costes, N.; Hammers, A. Multi-Atlas Attenuation Correction Supports Full Quantification of Static and Dynamic Brain PET Data in PET-MR. Phys. Med. Biol. 2017, 62, 2834–2858. [Google Scholar] [CrossRef]
  32. Ashburner, J.; Friston, K.J. Unified Segmentation. NeuroImage 2005, 26, 839–851. [Google Scholar] [CrossRef] [PubMed]
  33. Heckemann, R.A.; Keihaninejad, S.; Aljabar, P.; Rueckert, D.; Hajnal, J.V.; Hammers, A. Improving Intersubject Image Registration Using Tissue-Class Information Benefits Robustness and Accuracy of Multi-Atlas Based Anatomical Segmentation. NeuroImage 2010, 51, 221–227. [Google Scholar] [CrossRef] [PubMed]
  34. Hammers, A.; Allom, R.; Koepp, M.J.; Free, S.L.; Myers, R.; Lemieux, L.; Mitchell, T.N.; Brooks, D.J.; Duncan, J.S. Three-Dimensional Maximum Probability Atlas of the Human Brain, with Particular Reference to the Temporal Lobe. Hum. Brain Mapp. 2003, 19, 224–247. [Google Scholar] [CrossRef] [PubMed]
  35. Heckemann, R.A.; Hajnal, J.V.; Aljabar, P.; Rueckert, D.; Hammers, A. Automatic Anatomical Brain MRI Segmentation Combining Label Propagation and Decision Fusion. NeuroImage 2006, 33, 115–126. [Google Scholar] [CrossRef]
  36. Javier Meana, J.; Barturen, F.; Asier Garro, M.; García-Sevilla, J.A.; Fontán, A.; Zarranz, J.J. Decreased Density of Presynaptic A2-Adrenoceptors in Postmortem Brains of Patients with Alzheimer’s Disease. J. Neurochem. 1992, 58, 1896–1904. [Google Scholar] [CrossRef]
  37. Meana, J.J.; Barturen, F. α2-Adrenoceptors in the Brain of Suicide Victims: Increased Receptor Density Associated with Major Depression. Biol. Psychiatry 1992, 31, 471–490. [Google Scholar] [CrossRef]
  38. González, A.M.; Pascual, J.; Meana, J.J.; Barturen, F.; Del Arco, C.; Pazos, A.; García-Sevilla, J.A. Autoradiographic Demonstration of Increased A2-Adrenoceptor Agonist Binding Sites in the Hippocampus and Frontal Cortex of Depressed Suicide Victims. J. Neurochem. 1994, 63, 256–265. [Google Scholar] [CrossRef]
  39. Yuan, P.; Raz, N. Prefrontal Cortex and Executive Functions in Healthy Adults: A Meta-Analysis of Structural Neuroimaging Studies. Neurosci. Biobehav. Rev. 2014, 42, 180–192. [Google Scholar] [CrossRef]
  40. Volz, K.G.; Schubotz, R.I.; von Cramon, D.Y. Decision-Making and the Frontal Lobes. Curr. Opin. Neurol. 2006, 19, 401–406. [Google Scholar] [CrossRef]
  41. Rolls, E.T. The Functions of the Orbitofrontal Cortex. Brain Cogn. 2004, 55, 11–29. [Google Scholar] [CrossRef]
  42. Schall, J.D.; Stuphorn, V.; Brown, J.W. Monitoring and Control of Action by the Frontal Lobes. Neuron 2002, 36, 309–322. [Google Scholar] [CrossRef] [PubMed]
  43. Chayer, C.; Freedman, M. Frontal Lobe Functions. Curr. Neurol. Neurosci. Rep. 2001, 1, 547–552. [Google Scholar] [CrossRef] [PubMed]
  44. Talley, E.M.; Rosin, D.L.; Lee, A.; Guyenet, P.G.; Lynch, K.R. Distribution of α2A-Adrenergic Receptor-like Immunoreactivity in the Rat Central Nervous System. J. Comp. Neurol. 1996, 372, 111–134. [Google Scholar] [CrossRef]
  45. Strazielle, C.; Lalonde, R.; Hébert, C.; Reader, T.A. Regional Brain Distribution of Noradrenaline Uptake Sites, and of α1-α2- and Beta-Adrenergic Receptors in PCD Mutant Mice: A Quantitative Autoradiographic Study. Neuroscience 1999, 94, 287–304. [Google Scholar] [CrossRef] [PubMed]
  46. Pérez-Santos, I.; Palomero-Gallagher, N.; Zilles, K.; Cavada, C. Distribution of the Noradrenaline Innervation and Adrenoceptors in the Macaque Monkey Thalamus. Cereb. Cortex 2021, 31, 4115–4139. [Google Scholar] [CrossRef]
  47. Landau, A.M.; Doudet, D.J.; Jakobsen, S. Amphetamine Challenge Decreases Yohimbine Binding to A2 Adrenoceptors in Landrace Pig Brain. Psychopharmacology 2012, 222, 155–163. [Google Scholar] [CrossRef]
  48. Wilkinson, M.; Herdon, H.; Pearce, M.; Wilson, C. Radioligand Binding Studies on Hypothalamic Noradrenergic Receptors during the Estrous Cycle or after Steroid Injection in Ovariectomized Rats. Brain Res. 1979, 168, 652–655. [Google Scholar] [CrossRef]
  49. Wilkinson, M.; Herdon, H.J. Diethylstilbestrol Regulates the Number of A- and -Adrenergic Binding Sites in Incubated Hypothalamus and Amygdala. Brain Res. 1982, 248, 79–85. [Google Scholar] [CrossRef]
  50. Karkanias, G.B.; Etgen, A.M. Estradiol Reduction of the Agonist High Affinity Form of the Alpha 2-Adrenoceptor in the Hypothalamus of Female Rats: Identification as the Alpha 2D Subtype. Mol. Pharmacol. 1994, 45, 509–516. [Google Scholar]
  51. Karkanias, G.B.; Etgen, A.M. Estradiol Attenuates Alpha 2-Adrenoceptor-Mediated Inhibition of Hypothalamic Norepinephrine Release. J. Neurosci. 1993, 13, 3448–3455. [Google Scholar] [CrossRef]
  52. Eaton, W.W.; Kessler, R.C.; Wittchen, H.U.; Magee, W.J. Panic and Panic Disorder in the United States. Am. J. Psychiatry 1994, 151, 413–420. [Google Scholar] [CrossRef] [PubMed]
  53. Oquendo, M.A.; Ellis, S.P.; Greenwald, S.; Malone, K.M.; Weissman, M.M.; Mann, J.J. Ethnic and Sex Differences in Suicide Rates Relative to Major Depression in the United States. Am. J. Psychiatry 2001, 158, 1652–1658. [Google Scholar] [CrossRef] [PubMed]
  54. Bylund, D.B. Pharmacological Characteristics of Alpha-2 Adrenergic Receptor Subtypes. Ann. N. Y. Acad. Sci. 1995, 763, 1–7. [Google Scholar] [CrossRef] [PubMed]
  55. Altman, J.D.; Trendelenburg, A.U.; Macmillan, L.; Bernstein, D.; Limbird, L.; Starke, K.; Kobilka, B.K.; Hein, L. Abnormal Regulation of the Sympathetic Nervous System in α2A-Adrenergic Receptor Knockout Mice. Mol. Pharmacol. 1999, 56, 154–161. [Google Scholar] [CrossRef] [PubMed]
  56. Hein, L.; Altman, J.D.; Kobilka, B.K. Two Functionally Distinct A2-Adrenergic Receptors Regulate Sympathetic Neurotransmission. Nature 1999, 402, 181. [Google Scholar] [CrossRef]
  57. Vonend, O.; Habbel, S.; Stegbauer, J.; Roth, J.; Hein, L.; Rump, L.C. α2A-Adrenoceptors Regulate Sympathetic Transmitter Release in Mice Kidneys. Br. J. Pharmacol. 2007, 150, 121–127. [Google Scholar] [CrossRef]
  58. Bücheler, M.M.; Hadamek, K.; Hein, L. Two A2-Adrenergic Receptor Subtypes, A2A and A2C, Inhibit Transmitter Release in the Brain of Gene-Targeted Mice. Neuroscience 2002, 109, 819–826. [Google Scholar] [CrossRef]
  59. Scheibner, J.; Trendelenburg, A.U.; Hein, L.; Starke, K. α2-Adrenoceptors Modulating Neuronal Serotonin Release: A Study in α2-Adrenoceptor Subtype-Deficient Mice. Br. J. Pharmacol. 2001, 132, 925–933. [Google Scholar] [CrossRef]
  60. Langer, S.Z. Presynaptic Regulation of the Release of Catecholamines. Pharmacol. Rev. 1980, 32, 337–362. [Google Scholar] [CrossRef]
  61. Heal, D.J.; Butler, S.A.; Prow, M.R.; Buckett, W.R. Quantification of Presynaptic α2-Adrenoceptors in Rat Brain after Short-Term DSP-4 Lesioning. Eur. J. Pharmacol. 1993, 249, 37–41. [Google Scholar] [CrossRef]
  62. Szabadi, E. Functional Neuroanatomy of the Central Noradrenergic System. J. Psychopharmacol. 2013, 27, 659–693. [Google Scholar] [CrossRef] [PubMed]
  63. Langer, S.Z. Presynaptic Receptors and Modulation of Neurotransmission: Pharmacological Implications and Therapeutic Relevance. Trends Neurosci. 1980, 3, 110–112. [Google Scholar] [CrossRef]
Biomolecules 13 00843 g001 550
Figure 1. Widespread distribution of α2-ARs in the living human brain. Color bar gives estimates of BPND in units of mL.cm−3. In order to facilitate the use of this map, the average parametric image of BPND values of this dataset can be downloaded and used for any purpose with a simple request to the corresponding author.
Figure 1. Widespread distribution of α2-ARs in the living human brain. Color bar gives estimates of BPND in units of mL.cm−3. In order to facilitate the use of this map, the average parametric image of BPND values of this dataset can be downloaded and used for any purpose with a simple request to the corresponding author.
Biomolecules 13 00843 g001
Biomolecules 13 00843 g002 550
Figure 2. Statistical parametric maps comparing females to males. Data are surface-rendered onto the T1-weighted average reference brain provided by SPM12 using a voxel threshold of p < 0.005 (uncorrected) without cluster correction (k = 100 voxels). (A) Increase in [11C]yohimbine binding in female compared with male subjects is observed bilaterally in the hippocampus. (B) Increase in [11C]yohimbine binding in male compared with female subjects is observed in the orbital gyrus, superior frontal gyrus, and the middle and superior temporal gyrus, as well as the superior parietal and angular gyrus.
Figure 2. Statistical parametric maps comparing females to males. Data are surface-rendered onto the T1-weighted average reference brain provided by SPM12 using a voxel threshold of p < 0.005 (uncorrected) without cluster correction (k = 100 voxels). (A) Increase in [11C]yohimbine binding in female compared with male subjects is observed bilaterally in the hippocampus. (B) Increase in [11C]yohimbine binding in male compared with female subjects is observed in the orbital gyrus, superior frontal gyrus, and the middle and superior temporal gyrus, as well as the superior parietal and angular gyrus.
Biomolecules 13 00843 g002
Table
Table 1. Regional distribution of α2-ARs in the human brain.
Table 1. Regional distribution of α2-ARs in the human brain.
[11C]yohimbine BPND
FemalesMalesAll
Hippocampus0.67 ± 0.230.55 ± 0.170.61 ± 0.21
Occipital Lobe0.57 ± 0.210.60 ± 0.200.58 ± 0.20
Cingulate Gyrus0.55 ± 0.140.56 ± 0.150.56 ± 0.14
Frontal Lobe0.50 ± 0.170.54 ± 0.160.52 ± 0.17
Parietal Lobe0.45 ± 0.130.51 ± 0.140.48 ± 0.14
Thalamus0.46 ± 0.160.49 ± 0.130.48 ± 0.15
Parahippocampus0.42 ± 0.120.44 ± 0.120.43 ± 0.12
Insula0.42 ± 0.130.43 ± 0.150.42 ± 0.14
Temporal Lobe0.36 ± 0.140.39 ± 0.150.38 ± 0.14
Basal Ganglia0.30 ± 0.180.32 ± 0.180.31 ± 0.18
Amygdala0.29 ± 0.100.30 ± 0.100.30 ± 0.10
Cerebellum0.23 ± 0.180.31 ± 0.120.27 ± 0.16
Raphe0.22 ± 0.160.26 ± 0.180.24 ± 0.17
Bold values indicate an effect of sex.
Table
Table 2. Statistical differences in [11C]yohimbine binding between regions.
Table 2. Statistical differences in [11C]yohimbine binding between regions.
HippocampusOccipital LobeCingulate GyrusFrontal LobeParietal LobeThalamusParahippocampusInsulaTemporal LobeBasal GangliaAmygdalaCerebellumRaphe
Hippocampus
Occipital Lobens
Cingulate Gyrusnsns
Frontal Lobe******ns
Parietal Lobe************
Thalamus*******nsns
Parahippocampus************nsns
Insula***************nsns
Temporal Lobe******************ns***
Basal Ganglia***************************
Amygdala**************************ns
Cerebellum***************************nsns
Raphe*****************************nsns
ns: nonsignificant (ps > 0.1), *** = p < 0.0005, ** = p < 0.005, * = p < 0.05.
Table
Table 3. Differences in [11C]yohimbine binding between subregions of the frontal lobe.
Table 3. Differences in [11C]yohimbine binding between subregions of the frontal lobe.
Inferior Frontal GyrusMiddle Frontal GyrusOrbital GyrusPrecentral GyrusPresubgenual ACCStraight GyrusSubcallosal AreaSubgenual ACCSuperior Frontal Gyrus
Inferior Frontal Gyrus
Middle Frontal Gyrusns
Orbital Gyrus****ns
Precentral Gyrusns********
Presubgenual ACC*nsns****
Straight Gyrus*****************
Subcallosal Area*********************
Subgenual ACCns********ns********ns
Superior Frontal Gyrusnsns***ns***********
(ns: nonsignificant, **** = p < 0.001, *** = p < 0.005, ** = p < 0.01, * = p < 0.05).
Table
Table 4. Subregional distribution of α2-ARs in the human brain in fractionated ROIs. Bold values indicate an effect of sex.
Table 4. Subregional distribution of α2-ARs in the human brain in fractionated ROIs. Bold values indicate an effect of sex.
[11C]yohimbine BPND
FemalesMalesAll
Cuneus0.67 ± 0.170.71 ± 0.160.68 ± 0.17
Lingual Gyrus0.65 ± 0.180.67 ± 0.160.66 ± 0.17
Straight Gyrus0.65 ± 0.150.65 ± 0.140.65 ± 0.14
Posterior Cingulate Cortex0.60 ± 0.150.62 ± 0.140.61 ± 0.14
Hippocampus0.67 ± 0.230.55 ± 0.170.61 ± 0.21
Orbital Gyrus0.55 ± 0.170.60 ± 0.140.58 ± 0.16
Presubgenual ACC0.56 ± 0.180.57 ± 0.150.57 ± 0.16
Middle Frontal Gyrus0.49 ± 0.140.58 ± 0.160.54 ± 0.15
Anterior Cingulate Cortex0.51 ± 0.120.51 ± 0.140.51 ± 0.13
Superior Frontal Gyrus0.49 ± 0.150.53 ± 0.150.51 ± 0.15
Superior Parietal Gyrus0.47 ± 0.130.52 ± 0.140.50 ± 0.14
Inferior Frontal Gyrus0.46 ± 0.110.51 ± 0.140.49 ± 0.13
Supramarginal Gyrus0.46 ± 0.130.50 ± 0.140.48 ± 0.14
Angular Gyrus0.44 ± 0.140.51 ± 0.150.48 ± 0.15
Thalamus0.46 ± 0.160.49 ± 0.130.48 ± 0.15
Posterior Temporal Lobe0.46 ± 0.130.48 ± 0.130.47 ± 0.13
Postcentral Gyrus0.43 ± 0.130.49 ± 0.140.46 ± 0.14
Parahippocampus0.42 ± 0.120.44 ± 0.120.43 ± 0.12
Precentral Gyrus0.40 ± 0.130.46 ± 0.140.43 ± 0.14
Subgenual ACC0.42 ± 0.130.41 ± 0.120.42 ± 0.13
Insula0.42 ± 0.130.43 ± 0.150.42 ± 0.14
Fusiform gyrus0.41 ± 0.120.41 ± 0140.41 ± 0.13
Nucleus Accumbens0.40 ± 0.160.41 ± 0.130.41 ± 0.14
Lateral Occipital Lobe0.39 ± 0.130.42 ± 0.140.40 ± 0.14
Putamen0.37 ± 0.180.43 ± 0.170.40 ± 0.17
Pallidum0.37 ± 0.140.41 ± 0.160.39 ± 0.15
Superior Temporal Gyrus0.36 ± 0.140.39 ± 0.160.38 ± 0.15
Middle and Inferior Temporal Gyrus0.37 ± 0.120.36 ± 0.130.37 ± 0.12
Subcallosal Area0.36 ± 0.140.35 ± 0.120.35 ± 0.13
Anterior Temporal Lobe0.30 ± 0.130.33 ± 0.130.32 ± 0.13
Amygdala0.29 ± 0.100.30 ± 0.100.30 ± 0.10
Cerebellum0.23 ± 0.180.31 ± 0.120.27 ± 0.16
Raphe0.22 ± 0.160.26 ± 0.180.24 ± 0.17
Substantia Nigra0.20 ± 0.140.19 ± 0.140.19 ± 0.14
Caudate Nucleus0.15 ± 0.140.19 ± 0.090.17 ± 0.12
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Laurencin, C.; Lancelot, S.; Merida, I.; Costes, N.; Redouté, J.; Le Bars, D.; Boulinguez, P.; Ballanger, B. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET. Biomolecules 2023, 13, 843. https://doi.org/10.3390/biom13050843

AMA Style

Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, Ballanger B. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET. Biomolecules. 2023; 13(5):843. https://doi.org/10.3390/biom13050843

Chicago/Turabian Style

Laurencin, Chloé, Sophie Lancelot, Inès Merida, Nicolas Costes, Jérôme Redouté, Didier Le Bars, Philippe Boulinguez, and Bénédicte Ballanger. 2023. "Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET" Biomolecules 13, no. 5: 843. https://doi.org/10.3390/biom13050843

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop